Clinical Trials
13 trialsNCT04981119 2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
NCT05056077 2026-06-02
TTBF
University of California, San Francisco
Phase NA Active not recruiting
NCT03289962 2026-05-29
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT05225428 2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT06885424 2026-05-20
DESCENT-1
A2 Biotherapeutics Inc.
Enrolling by invitation
NCT05184790 2026-05-19
LEARN
University of Sydney
Recruiting
NCT06673329 2026-05-13
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Phase 1 Recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT07555210 2026-05-06
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Vanderbilt-Ingram Cancer Center
Phase NA Recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT00579514 2026-04-07
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting